About this episode
In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at [email protected]
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time The Decibel publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Decibel
How much AI music is in your playlist?
The Decibel
What war in Iran means for Canadian oil
The Decibel
Why holding government to account in Ontario could get harder
The Decibel
Behind schedule and over budget: Why do we keep building LRTs?
The Decibel